Published in Nat Rev Neurol on March 01, 2010
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol (2012) 1.41
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology (2007) 4.72
Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol (2006) 3.73
Clinical practice. Optic neuritis. N Engl J Med (2006) 2.61
Optical coherence tomography and disease subtype in multiple sclerosis. Neurology (2007) 2.56
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain (2007) 2.18
Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology (2009) 1.44
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Uhthoff and his symptom. J Neuroophthalmol (1995) 1.08
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage (2007) 5.23
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. Neuroimage (2009) 3.07
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol (2010) 2.99
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Factors that influence adherence with disease-modifying therapy in MS. J Neurol (2009) 2.67
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology (2012) 2.54
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44
The King-Devick test and sports-related concussion: study of a rapid visual screening tool in a collegiate cohort. J Neurol Sci (2011) 2.43
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol (2002) 2.05
Laser pointer visual field screening. J Neuroophthalmol (2003) 2.03
High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain (2007) 2.03
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (2011) 2.02
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Diffusion tensor magnetic resonance imaging of Wallerian degeneration in rat spinal cord after dorsal root axotomy. J Neurosci (2009) 1.79
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Retinal layer segmentation of macular OCT images using boundary classification. Biomed Opt Express (2013) 1.67
Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66
Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis. Neuroimage (2007) 1.62
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Near infrared muscle spectroscopy in patients with Friedreich's ataxia. Muscle Nerve (2002) 1.53
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology (2012) 1.51
Functional visual loss in idiopathic intracranial hypertension. Ophthalmology (2009) 1.51
Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Mult Scler (2013) 1.47
Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology (2013) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS (2011) 1.45
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain (2010) 1.45
The role of unilateral temporal artery biopsy. Ophthalmology (2003) 1.44
Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol (2009) 1.43
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol (2005) 1.40
Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain (2009) 1.38
Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia (2007) 1.37
Optic nerve biopsy in the management of progressive optic neuropathy. J Neuroophthalmol (2012) 1.37
In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. J Neurol (2012) 1.36
Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. Ophthalmology (2013) 1.36
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest (2002) 1.36
Sports-related concussion: Anonymous survey of a collegiate cohort. Neurol Clin Pract (2013) 1.35
Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application. Magn Reson Med (2006) 1.34
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol (2004) 1.31
Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler (2010) 1.29